ESSEX BIO-TECH Executes HKD0.36 Million Share Buyback, Reducing Free Float by 0.02%

Bulletin Express06-18

Essex Bio-Technology Limited reported the repurchase of 135,000 ordinary shares on 18 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The shares were bought on-market at prices ranging from HKD 2.63 to HKD 2.65, resulting in a volume-weighted average cost of HKD 2.6411 per share and an aggregate cash outlay of approximately HKD 0.36 million.

Following the transaction, the company’s outstanding issued share capital (excluding treasury shares) fell to 566.87 million shares from 567.01 million, representing a 0.02% reduction. All repurchased shares have been retained as treasury stock, leaving the total issued share count unchanged at 567.01 million.

The buyback forms part of a broader mandate approved by shareholders on 26 May 2026, which authorises Essex Bio-Tech to repurchase up to 56.70 million shares. To date, only 135,000 shares—or 0.02% of the approved limit—have been utilised, leaving capacity for an additional 56.57 million shares.

In line with Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 18 July 2026. Management confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137415461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137415461","market":"hk","top_or_hot":-1,"title":"ESSEX BIO-TECH Executes HKD0.36 Million Share Buyback, Reducing Free Float by 0.02%","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited reported the repurchase of 135,000 ordinary shares on 18 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The shares were bought on-market at prices ranging from HKD 2.63 to HKD 2.65, resulting in a volume-weighted average cost of HKD 2.6411 per share and an aggregate cash outlay of approximately HKD 0.36 million.</p>\n<p>Following the transaction, the company’s outstanding issued share capital (excluding treasury shares) fell to 566.87 million shares from 567.01 million, representing a 0.02% reduction. All repurchased shares have been retained as treasury stock, leaving the total issued share count unchanged at 567.01 million.</p>\n<p>The buyback forms part of a broader mandate approved by shareholders on 26 May 2026, which authorises Essex Bio-Tech to repurchase up to 56.70 million shares. To date, only 135,000 shares—or 0.02% of the approved limit—have been utilised, leaving capacity for an additional 56.57 million shares.</p>\n<p>In line with Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 18 July 2026. Management confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSEX BIO-TECH Executes HKD0.36 Million Share Buyback, Reducing Free Float by 0.02%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSEX BIO-TECH Executes HKD0.36 Million Share Buyback, Reducing Free Float by 0.02%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-18 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited reported the repurchase of 135,000 ordinary shares on 18 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The shares were bought on-market at prices ranging from HKD 2.63 to HKD 2.65, resulting in a volume-weighted average cost of HKD 2.6411 per share and an aggregate cash outlay of approximately HKD 0.36 million.</p>\n<p>Following the transaction, the company’s outstanding issued share capital (excluding treasury shares) fell to 566.87 million shares from 567.01 million, representing a 0.02% reduction. All repurchased shares have been retained as treasury stock, leaving the total issued share count unchanged at 567.01 million.</p>\n<p>The buyback forms part of a broader mandate approved by shareholders on 26 May 2026, which authorises Essex Bio-Tech to repurchase up to 56.70 million shares. To date, only 135,000 shares—or 0.02% of the approved limit—have been utilised, leaving capacity for an additional 56.57 million shares.</p>\n<p>In line with Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 18 July 2026. Management confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1137415461","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137415461","pubTimestamp":1781779581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited reported the repurchase of 135,000 ordinary shares on 18 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The shares were...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"亿胜生物执行36万港元股份回购，自由流通量减少0.02%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited reported the repurchase of 135,000 ordinary shares on 18 June 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The shares were bought on-market at prices ranging from HKD 2.63 to HKD 2.65, resulting in a volume-weighted average cost of HKD 2.6411 per share and an aggregate cash outlay of approximately HKD 0.36 million.\nFollowing the transaction, the company’s outstanding issued share capital (excluding treasury shares) fell to 566.87 million shares from 567.01 million, representing a 0.02% reduction. All repurchased shares have been retained as treasury stock, leaving the total issued share count unchanged at 567.01 million.\nThe buyback forms part of a broader mandate approved by shareholders on 26 May 2026, which authorises Essex Bio-Tech to repurchase up to 56.70 million shares. To date, only 135,000 shares—or 0.02% of the approved limit—have been utilised, leaving capacity for an additional 56.57 million shares.\nIn line with Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 18 July 2026. Management confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137415461","isCrawlerRequest":true}